Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma

In the article cited above, there was an error in Figure 3B. A corrected version of Figure 3B is attached.

Figure 3.

Korean asthma control test (K-ACT) at week 0, 16, and 24. (A) Mean ± standard error of the mean K-ACT. (B) Asthma control levels. K-ACT was improved after omalizumab treatment, and the proportions of “partly controlled” and “controlled” on week 16 and week 24 were higher than those at week 0. ^ap < 0.001, ^bp < 0.005 compared to K-ACT at week 0.

We apologize for any inconvenience that this may have caused.